Among four Dividend Aristocrats highlighted a year ago, AbbVie and Becton Dickinson outperformed the market with strong dividend growth and solid financials, while Procter & Gamble and Brown-Forman lagged in price but maintained reliable dividend payments. AbbVie led with a 47.4% gain driven by immunology drug growth, and Becton Dickinson rallied 25.5% supported by strong cash flow. New promising picks include Albemarle, Medtronic, and Stanley Black & Decker, each showing improved dividend coverage and growth potential across cyclical, defensive, and industrial sectors. The key takeaway is that Dividend Aristocrats provide steady income growth regardless of short-term price fluctuations.
Becton, Dickinson and Company (BD) reported strong Q3 fiscal 2026 results, surpassing analyst expectations with an EPS of $3.23 versus the estimated $3.14, and revenue of $4.98 billion beating the $4.89 billion forecast. Despite a year-over-year EPS ...
BD (Becton, Dickinson and Company) posted a 5.4% increase in Q3 revenue to $5.0 billion, driven by growth across its Medical Essentials, Connected Care, BioPharma Systems, and Interventional segments. Adjusted diluted EPS rose to $3.23, and cash from...
